Smith & Nephew Wows With a 50% Dividend Increase

Don't let it get away!

Keep track of the stocks that matter to you.

Help yourself with the Fool's FREE and easy new watchlist service today.

LONDON -- Smith & Nephew (LSE: SN.L  ) pleased the market today by announcing a 50% increase to the interim dividend and a new progressive dividend policy that could significantly improve the shares' currently unimpressive 2% dividend yield.

Compared to other big names in the health-care sector, like FTSE 100 stalwarts GlaxoSmithKline (LSE: GSK.L  ) and AstraZeneca (LSE: AZN.L  ) , which boast yields of 4.6% and 3.8%, respectively, Smith & Nephew is downright disappointing if you're an income investor.

However, one year into new CEO Olivier Bohuon's restructuring plan, the company's margins are showing improvement, which is translating to stronger cash flow; free cash flow (cash from operations less spending on capital) was up 26% in the quarter. This, along with the 66 million pounds in cash from the sale of a 51% stake in the company's experimental biologics business, helped pay down 133 million pounds in debt in the quarter and provided the company with a net cash balance of 96 million pounds.

Bohuon had previously said excess cash would be aimed at acquisitions to complement the company's newly focused research efforts, but the Board has apparently heard the appeals from shareholders for some sharing of the wealth.

Even with this newfound generosity Smith & Nephew likely won't be topping income investors' wish lists, but this free report from The Motley Fool -- "8 Shares Held By Britain's Super Investor" -- offers up some of the shares favored by one of the U.K.'s most successful income investors. Click here to download your free copy today.

Income shares can provide uncertainty in troubled times. 10 Steps To Making A Million In The Market is the very latest Motley Fool guide to help Britain invest. Better. We urge you to read the report today -- it's free.

Further Motley Fool investment opportunities

Nate does not own any shares discussed above. The Motley Fool owns shares of Smith & Nephew. The Motley Fool has a disclosure policy.
We Fools may not all hold the same opinions, but we all believe that
considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days.

Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1969635, ~/Articles/ArticleHandler.aspx, 10/24/2016 3:32:44 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 2 days ago Sponsored by:
DOW 18,145.71 -16.64 -0.09%
S&P 500 2,141.16 -0.18 -0.01%
NASD 5,257.40 15.57 0.30%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes